Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Colorcon
Johnson and Johnson
Medtronic
AstraZeneca

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

Litigation Details for Cumberland Pharmaceuticals Inc. v. Sagent Agila LLC (D. Del. 2012)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Cumberland Pharmaceuticals Inc. v. Sagent Agila LLC (D. Del. 2012)

Docket   Start Trial Date Filed 2012-06-26
Court District Court, D. Delaware Date Terminated 2013-11-01
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties CUMBERLAND PHARMACEUTICALS INC.; SAGENT AGILA LLC; SAGENT PHARMACEUTICALS INC.
Patents 8,148,356
Attorneys Danielle A. Duszczyszyn; Joseph James Bellew; Laura P. Masurovsky; Marilyn Neiman; Mark J. Feldstein; Martin B. Pavane
Link to Docket External link to docket
Small Molecule Drugs cited in Cumberland Pharmaceuticals Inc. v. Sagent Agila LLC
The small molecule drug covered by the patent cited in this case is   Start Trial .

Details for Cumberland Pharmaceuticals Inc. v. Sagent Agila LLC (D. Del. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-06-26 1 Cumberland is the owner of U.S. Patent No. 8,148,356 (“the ’356 patent”), entitled “Acetylcysteine… (A) A declaration that United States Patent No. 8,148,356 is valid and enforceable;   (…is a complaint for patent infringement and for declaratory judgment of patent infringement. The jurisdiction… Count I - Patent Infringement of the ’356 Patent   23. Cumberland…expiration of the ’356 patent, Defendants infringed one or more claims of the ’356 patent under 35 U.S.C External link to document
2013-11-01 18 certification contending that Cumberland's U.S. Patent No. 8,148,356, entitled "Acetylcysteine Composition…#39;356 patent (Count I) and seeks a declaratory judgment of infringement ofthe '356 patent (Count …chelating agents. (' 356 patent at col. 4 lines 7-16) In fact, the patent identifies EDTA as a …the reasons that follow. 1. This patent litigation action arises under the Hatch-Waxman…Composition and Uses Therefor" ("the '356 patent"), was invalid, unenforceable, or would not External link to document
2013-12-10 19 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,148,356. (ntl) (Entered: 12…2012 1 November 2013 1:12-cv-00825-LPS Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Johnson and Johnson
Harvard Business School
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.